USANA Health Sciences (USNA) Stock Overview
Develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
USNA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
USANA Health Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.91 |
| 52 Week High | US$38.32 |
| 52 Week Low | US$16.60 |
| Beta | 0.77 |
| 1 Month Change | 13.06% |
| 3 Month Change | 14.82% |
| 1 Year Change | -32.62% |
| 3 Year Change | -67.44% |
| 5 Year Change | -80.23% |
| Change since IPO | 3,167.28% |
Recent News & Updates
Recent updates
Narrative Update • Jun 01
USNA: Skincare And Wellness Launches Will Support Future Upside Potential
Analysts have adjusted their price target for USANA Health Sciences to $39.00. Updated assumptions around discount rate, revenue growth, profit margin, and future P/E have shaped this new view on the stock.Analysis Article • May 08
Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) just kicked off its latest first-quarter results with some...Narrative Update • Apr 26
USNA: Costco Expansion Of New Wellness Beverage Will Support Upside
Analysts have maintained their $39.0 price target for USANA Health Sciences, noting that small changes in the discount rate, revenue growth, profit margin, and future P/E assumptions in their updated models largely offset one another. What's in the News USANA Malaysia hosted a large slow jogging event on April 11, 2026, tied to the launch of its Vitamin D product, attracting over 1,000 onsite and online participants and earning a Malaysia Book of Records title for simultaneous acupressure slow jogging (Key Developments).Narrative Update • Apr 08
USNA: Costco Beverage Rollout And CEO Return Will Support Upside
The updated analyst price target for USANA Health Sciences now aligns with a fair value estimate of $39.00, as analysts fine tune their assumptions for discount rate, revenue, profit margin and future P/E to reflect current conditions. What's in the News Subsidiary Rise Wellness launched Protein Pop Plus, a clear, carbonated ready to drink protein beverage with 30 grams of protein per 12 ounce can, now available at all 607 Costco locations across the United States, expanding on the original Protein Pop line sold at Target stores (Key Developments).Narrative Update • Mar 25
USNA: CEO Return And Costco Distribution Expansion Will Support Future Upside
Analysts have made only a minimal adjustment to their fair value estimate for USANA Health Sciences, keeping it effectively unchanged at about $39.00. Small tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions offset each other.Narrative Update • Mar 09
USNA: CEO Return And New Product Rollout Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at about $39.00. This reflects only minor adjustments to assumptions about the discount rate, revenue growth, profit margin, and future P/E ratio, rather than a change in their overall view of the stock.Seeking Alpha • Mar 05
USANA Looks Like An Undervalued Turnaround Stock
Summary USANA Health Sciences is executing a strategic pivot from its declining MLM core to high-growth brands Hiya and Rise Wellness. Hiya’s Disney collaboration and subscription model drive projected 23% revenue growth, while Rise Wellness secures major retail distribution for Protein Pop. USNA trades at a significant valuation discount (EV/EBITDA 2.67), with a projected 2026 target price of $24.33—25% above current levels. I rate USNA a buy, as growth segments and a strong balance sheet outweigh risks from the MLM decline and business model transition. Read the full article on Seeking AlphaNarrative Update • Feb 22
USNA: CEO Return And Share Repurchases Will Support Future Upside
Analysts have nudged their price target for USANA Health Sciences slightly higher to $39, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which together point to a more refined view of the company’s valuation profile. What's in the News USANA Health Sciences plans to complete its long running share repurchase program announced in December 2015, having repurchased 8,544,925 shares, or 39.11%, for a total of $678.7 million.Narrative Update • Feb 08
USNA: CEO Transition To Kevin Guest Will Support Future Upside
Analysts have held their price target for USANA Health Sciences at about $39.00. This reflects updated assumptions for a slightly lower discount rate, revenue growth, profit margin, and future P/E that together point to a broadly unchanged valuation view.Narrative Update • Jan 24
USNA: Leadership Return And Index Removals Will Support Future Upside
Analysts have maintained their price target for USANA Health Sciences at US$39.00. This reflects a view that modestly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E still support the same fair value estimate.Narrative Update • Jan 07
USNA: Index Removals And Steady Outlook Will Support Future Upside Potential
Analysts now hold their price target for USANA Health Sciences steady at about US$39, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and forward P/E assumptions rather than a change in their overall view of the stock. What's in the News USANA Health Sciences, Inc.Narrative Update • Dec 23
USNA: Index Removals Will Create Future Opportunity For Undervalued Upside Potential
Analysts have modestly raised their price target on USANA Health Sciences to 39.00 dollars from 39.00 dollars, reflecting slightly lower discount rate assumptions, materially higher projected revenue growth, a modestly lower profit margin outlook, and a marginally richer expected future price to earnings multiple. What's in the News Removed as a constituent from the S&P SmallCap 600 index, reducing passive index fund ownership and visibility among small cap investors (Index change notice).Narrative Update • Dec 09
USNA: Active Acquisition Pursuits Will Drive Future Business Diversification Ahead
Analysts have modestly raised their price target on USANA Health Sciences to approximately $39.00, citing slightly higher long term growth assumptions and a marginal uptick in expected valuation multiples. What's in the News USANA Health Sciences was removed as a constituent from the S&P 600, S&P 1000, and S&P Composite 1500 indexes, as well as the S&P 600 Consumer Staples sector index, potentially reducing passive index fund ownership of the stock (Index Constituent Drops).Narrative Update • Nov 25
USNA: Active M&A Efforts Will Drive Positive Business Diversification Ahead
Analysts have reiterated their price target for USANA Health Sciences at $39.00, citing consistent assumptions in revenue growth, profit margin, and valuation multiples. These factors support a stable outlook.Narrative Update • Nov 08
USNA: Future Diversification Plans Will Drive Renewed Investor Optimism
Analysts have maintained their price target for USANA Health Sciences steady at $39.00. They cited consistent growth and profitability estimates as justification for holding the previous valuation.Narrative Update • Oct 24
Share Repurchases And Product Expansion Will Drive Profitability And Brand Recognition
Analysts have revised their price target for USANA Health Sciences to $39.00. This reflects a recalibrated outlook based on modest revenue growth and improved profit margin expectations.Analysis Article • Oct 16
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
USANA Health Sciences, Inc. ( NYSE:USNA ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Oct 11
Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...Narrative Update • Oct 10
Modernized Sales Model And International Expansion Will Deliver Success
Analysts have significantly lowered their price target for USANA Health Sciences from $61 to $39. They cite reduced expectations for revenue growth and profit margins as key factors in the revised outlook.Analysis Article • Jul 18
USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough
USANA Health Sciences, Inc.'s ( NYSE:USNA ) price-to-earnings (or "P/E") ratio of 16.3x might make it look like a buy...Analysis Article • May 12
Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package
Key Insights USANA Health Sciences to hold its Annual General Meeting on 19th of May Total pay for CEO Jim Brown...Analysis Article • Apr 08
The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%
The USANA Health Sciences, Inc. ( NYSE:USNA ) share price has fared very poorly over the last month, falling by a...Analysis Article • Apr 04
There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analysis Article • Dec 09
Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?
USANA Health Sciences, Inc. ( NYSE:USNA ), might not be a large cap stock, but it received a lot of attention from a...Analysis Article • Sep 26
USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
New Narrative • Sep 24
India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins
Expansion into India and strategic acquisitions offer significant growth opportunities for USANA, potentially boosting revenue and diversifying its market presence.Analysis Article • Sep 08
Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?
While USANA Health Sciences, Inc. ( NYSE:USNA ) might not have the largest market cap around , it saw significant share...Analysis Article • Jul 26
USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
As you might know, USANA Health Sciences, Inc. ( NYSE:USNA ) last week released its latest second-quarter, and things...Shareholder Returns
| USNA | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 10.4% | 6.1% | 0.8% |
| 1Y | -32.6% | -11.9% | 24.2% |
Return vs Industry: USNA underperformed the US Personal Products industry which returned -15.5% over the past year.
Return vs Market: USNA underperformed the US Market which returned 21.5% over the past year.
Price Volatility
| USNA volatility | |
|---|---|
| USNA Average Weekly Movement | 5.9% |
| Personal Products Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: USNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: USNA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,570 | Kevin Guest | www.usana.com |
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration.
USANA Health Sciences, Inc. Fundamentals Summary
| USNA fundamental statistics | |
|---|---|
| Market cap | US$366.86m |
| Earnings (TTM) | US$8.87m |
| Revenue (TTM) | US$925.94m |
41.4x
P/E Ratio0.4x
P/S RatioIs USNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| USNA income statement (TTM) | |
|---|---|
| Revenue | US$925.94m |
| Cost of Revenue | US$207.84m |
| Gross Profit | US$718.09m |
| Other Expenses | US$709.22m |
| Earnings | US$8.87m |
Last Reported Earnings
Apr 04, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 77.55% |
| Net Profit Margin | 0.96% |
| Debt/Equity Ratio | 2.4% |
How did USNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 06:28 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/04/04 |
| Annual Earnings | 2026/01/03 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
USANA Health Sciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Scott Van Winkle | Canaccord Genuity |
| Stephanie Schiller Wissink | Jefferies LLC |